Erbitux trial flawed from the beginning, committee finds

Journal of the National Cancer Institute

Volumn 94, Issue 24, 2002, Pages 1824-1825

  Randal, Judith ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; IRINOTECAN;

ANTINEOPLASTIC ACTIVITY; CANCER REGRESSION; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG APPROVAL; DRUG MONITORING; DRUG POTENTIATION; DRUG RESPONSE; FINANCIAL MANAGEMENT; HUMAN; NOTE; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; QUALITY CONTROL;

EID: 0037132697     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.24.1824     Document Type: Note

References (0)